Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
102 results
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.390 - Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
D2.345 - Conformations of HVEM engaged in its Trans and Cis interactions are caused by two kinds of post-translational folding
D2.50 - Hereditary angioedema; single center experience
D3.17 - Systemic Histaminergic Findings in Children with Chronic Urticaria
D3.180 - Good patient adherence to sublingual immunotherapy for allergic rhinitis can be achieved, when ENT-physicians collaborate with pharmacies in a straightforward adherence programme
D3.308 - Frailty in elderly with C1 Inhibitor Hereditary Angioedema: first evidence from a monocentric ITACA cohort
D3.310 - Hereditary angioedema (HAE) with factor XIIa mutation successfully treated with icatibant as on-demand therapy and lanadelumab for long-term prophylaxis
D3.346 - Impact of local craniocerebral hypothermia on inflammatory cytokine production in ischemic stroke
D3.386 - A novel machine learning based gene expression signature for Atopic dermatitis
D3.51 - Using PEN-FAST score to guide prescription of alternative beta-lactam in penicillin-allergic patients by non-allergists
D1.252 - A model based economic evaluation to assess impact of Penicillin Allergy in COPD patients
Pagination
First page
First
Previous page
Previous
Page
1
Page
2
Page
3
Page
4
Current page
5
Page
6
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download